ArticleAntimicrobial agents and chemotherapy2013
In vitro susceptibility of Mycobacterium tuberculosis to trimethoprim and sulfonamides in France.
Article in Antimicrobial agents and chemotherapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Innovative Strategies in Drug Repurposing to Tackle Intracellular Bacterial Pathogens.Antibiotics (Basel, Switzerland) · 2024Review
- A case of multidrug-resistantRespirology case reports · 2021Article
- Repurposing Immunomodulatory Drugs to Combat Tuberculosis.Frontiers in immunology · 2021Review
- Malaria, tuberculosis and HIV: what's new? Contribution of the Institut Hospitalo-Universitaire Méditerranée Infection in updated data.New microbes and new infections · 2018Article
- Sulfadiazine Salicylaldehyde-Based Schiff Bases: Synthesis, Antimicrobial Activity and Cytotoxicity.Molecules (Basel, Switzerland) · 2017Article
- Susceptibilities of MDR Mycobacterium tuberculosis isolates to unconventional drugs compared with their reported pharmacokinetic/pharmacodynamic parameters.The Journal of antimicrobial chemotherapy · 2017Article
- Novel Sulfamethoxazole Ureas and Oxalamide as Potential Antimycobacterial Agents.Molecules (Basel, Switzerland) · 2017Article
- Repurposing and Revival of the Drugs: A New Approach to Combat the Drug Resistant Tuberculosis.Frontiers in microbiology · 2017Article
- Mycobacterium tuberculosis folate metabolism and the mechanistic basis for para-aminosalicylic acid susceptibility and resistance.Antimicrobial agents and chemotherapy · 2015Review
- Intra- and extracellular activities of trimethoprim-sulfamethoxazole against susceptible and multidrug-resistant Mycobacterium tuberculosis.Antimicrobial agents and chemotherapy · 2014Article
- A new strategy to fight antimicrobial resistance: the revival of old antibiotics.Frontiers in microbiology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Five type strains and 55 Mycobacterium tuberculosis complex clinical isolates were found resistant to trimethoprim with a MIC of >200 mg/liter and susceptible to both sulfadiazine and cotrimoxazole with a MIC90 of 10 mg/liter. Two M. canettii isolates uniquely yielded silent mutations C156 → T and G238 → C in the folP1 gene. Combined with scarce published data, these data indicate that sulfamides could be considered alternative antituberculous antibiotics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.